Effects of fixed orthodontic appliance with antihypertensive drugs on the body weight of experimental rats
Main Article Content
Abstract
Background: This study aims to investigate the effect of fixed orthodontic appliances and/or antihypertensive drugs on the weight of experimental rats. Materials and Methods: Thir-ty-six male Wistar albino rats were subjected to a split-mouth design study, in which an orthodontic appliance was inserted in one side to move the first molar mesially for 2 weeks while the other side acted as a control to tooth movement. The rats were allocated into three groups: group A (n = 12), without any pharmacological treatment; group B (n = 12), subcu-taneous injection of bisoprolol fumarate (5 mg/kg) daily; and group C (n = 12), subcutaneous injection of valsartan (10 mg/kg) daily. A fixed orthodontic appliance with a closing coil spring delivering 50 gm of force was used to move the first molar mesially while the incisors served as an anchor unit. The weight of the rats was measured on days 1 (the day of appli-ance insertion), 7, and 14. Results: No significant (P > 0.05) difference in the body weight of rats was found among the three groups at each time point; however, significant (P < 0.05) weight loss was noted after the first and second week of the experiment in all study groups. Conclusion: The body weight loss of rats following the insertion of a fixed orthodontic ap-pliance could be related to the effects of the appliance rather than the administered antihy-pertensive drugs.
Received date: 09-05-2022
Accepted date: 10-06-2022
Published date: 15-03-2023
Downloads
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licenses and Copyright
The following policy applies in The Journal of Baghdad College of Dentistry (JBCD):
# JBCD applies the Creative Commons Attribution (CC BY) license to articles and other works we publish. If you submit your paper for publication by JBCD, you agree to have the CC BY license applied to your work. Under this Open Access license, you as the author agree that anyone can reuse your article in whole or part for any purpose, for free, even for commercial purposes. Anyone may copy, distribute, or reuse the content as long as the author and original source are properly cited. This facilitates freedom in re-use and also ensures that JBCD content can be mined without barriers for the needs of research.
# If your manuscript contains content such as photos, images, figures, tables, audio files, videos, etc., that you or your co-authors do not own, we will require you to provide us with proof that the owner of that content (a) has given you written permission to use it, and (b) has approved of the CC BY license being applied to their content. We provide a form you can use to ask for and obtain permission from the owner. If you do not have owner permission, we will ask you to remove that content and/or replace it with other content that you own or have such permission to use.Don't assume that you can use any content you find on the Internet, or that the content is fair game just because it isn't clear who the owner is or what license applies.
# Many authors assume that if they previously published a paper through another publisher, they own the rights to that content and they can freely use that content in their paper, but that’s not necessarily the case, it depends on the license that covers the other paper. Some publishers allow free and unrestricted re-use of article content they own, such as under the CC BY license. Other publishers use licenses that allow re-use only if the same license is applied by the person or publisher re-using the content. If the paper was published under a CC BY license or another license that allows free and unrestricted use, you may use the content in your JBCD paper provided that you give proper attribution, as explained above.If the content was published under a more restrictive license, you must ascertain what rights you have under that license. At a minimum, review the license to make sure you can use the content. Contact that JBCD if you have any questions about the license. If the license does not permit you to use the content in a paper that will be covered by an unrestricted license, you must obtain written permission from the publisher to use the content in your JBCD paper. Please do not include any content in your JBCD paper which you do not have rights to use, and always give proper attribution.
# If any relevant accompanying data is submitted to repositories with stated licensing policies, the policies should not be more restrictive than CC BY.
# JBCD reserves the right to remove any photos, captures, images, figures, tables, illustrations, audio and video files, and the like, from any paper, whether before or after publication, if we have reason to believe that the content was included in your paper without permission from the owner of the content.
How to Cite
References
Krishnan V, Davidovitch Ze. Cellular, molecular, and tissue-level reactions to orthodontic force. Am J Orthod Dentofacial Orthop. 2006;129(4):469.
Doyle AE. Hypertension and vascular disease. Am J Hypertens. 1991;4(2 Pt 2): 103s-6s.
Gande V, Unhale S, Ingle S, Lende P, Pagore P, Biyani P. A review on types, treatment, awareness, prevention, patho-physiology and diagnosis of hypertension. IJARIIE. 2020; 6:1576-86.
Piko P, Llanaj E, Nagy K, Adany R. Genetic Background of Metabolically Healthy and Unhealthy Obesity Phenotypes in Hungarian Adult Sample Population. IJMS. 2023;24(6):5209.
DeGrazia D, Beauchamp TL. Beyond the 3 Rs to a more comprehensive framework of principles for animal research ethics. ILAR journal. 2019;60(3):308-17.
Ibrahim A, Gudhimella S, Pandruvada S, Huja S. Resolving differences between animal models for expedited orthodontic tooth movement. Orthod Craniofac Res. 2017; 20:72-6.
Farzam K, Jan A. Beta blockers. StatPearls [Internet]: StatPearls Publishing; 2022. (Crossref)
Velmurugan BK, Baskaran R, Huang C-Y. Detailed insight on β-adrenoceptors as therapeutic targets. Biomedicine & Pharmacotherapy. 2019; 117:109039.
Bazroon AA, Alrashidi NF. Bisoprolol. StatPearls [Internet]: StatPearls Publishing; 2022.
Graham S, Hammond-Jones D, Gamie Z, Polyzois I, Tsiridis E, Tsiridis E. The effect of beta-blockers on bone metabolism as potential drugs under investigation for osteoporosis and fracture healing. Expert Opin Investig Drugs. 2008;17(9):1281-99.
Sharif PS, Abdollahi M. A systematic review on the relationship between beta-blockers and bone health. IJP. 2010;6(5):577-83.
Alves Barreto AE, Balera Brito VG, Patrocinio MS, Ballassoni BB, Tfaile Frasnelli SC, Penha Oliveira SH. β1-adrenergic receptor but not β2 mediates osteogenic differentiation of bone marrow mesenchymal stem cells in normotensive and hypertensive rats. EJP. 2021; 911:174515.
Ghosh M, Majumdar SR. Antihypertensive medications, bone mineral density, and fractures: a review of old cardiac drugs that provides new insights into osteoporosis. Endocrine. 2014;46(3):397-405.
Naser NH, Alibeg AAA. Exacerbation of COVID 19 in Hypertensive Patients (A review). IJPS. 2021;30(2):23-30.
Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J. Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study. Hypertens Res. 2022;45(5):824-33.
Naharci MI, Taş0çi I, Sefer U, Doruk H, Bozoğlu E, Karaman M, et al. Influences of treatment with amlodipine and valsartan on bone turnover markers and OPG/RANKL/RANK system in newly diagnosed hypertensive adults; which is more beneficial? Türk Nefroloji Diyaliz ve Transplantasyon Dergisi. 2014;23(1):40-5.
Suleiman JB, Mohamed M, Bakar ABA. A systematic review on different models of inducing obesity in animals: Ad-vantages and limitations. J. Adv. Vet. Anim. Res. 2020;7(1):103-14.
Macedo CS, Capelletti SM, Mercadante MCS, Padovani CR, Spadella CT. Role of metabolic control on diabetic nephrop-athy. Acta Cir Bras. 2002; 17:370-6. doi: 10.1016/j.kint.2017.05.034.
Luaibi NM, Mohammed RA. Physiological and Hormonal Effects of Titanium Dioxide Nanoparticles on Thyroid Function and the Impact on Bodyweight in Male Rats. Baghdad Sci. J. 2023;20(2):0416.
Faradila F, Yuliarni S, Rika S, Nur IL. The Effect of Combination Ovariectomy and D-galactose Administration on Alz-heimer's Animal Model. Baghdad Sci. J. 2022;19(5):1021.
Strohm B. Ethanol. In: Wexler P, editor. Encyclopedia of Toxicology (Third Edition). Oxford: Academic Press; 2014. p. 488-91.
Liu Y, Wang J, Wang X, Liu P, Pang F. Solubility of Valsartan in Different Organic Solvents and Ethanol + Water Binary Mixtures from (278.15 to 313.15) K. J. Chem. Eng. 2009;54(3):986-8.
Alnajar HAAM, Al Groosh DH. The effects of calcitonin on post‐orthodontic relapse in rats. Clin Exp Dent Res. 2021;7(3):293-301.
Nogueira AVB, Marcantonio CC, de Molon RS, Leguizamón NDP, Silva RCL, Deschner J, et al. Experimental models of orthodontic tooth movement and their effects on periodontal tissues remodelling. Arch. Oral Biol. 2021; 130:105216.
Krishnan V, Zahrowski JJ, Davidovitch Ze. The Effect of Drugs, Hormones, and Diet on Orthodontic Tooth Movement. Biological Mechanisms of Tooth Movement. 2021:199-215.
Kovacić D, Marinsek M, Gobec L, Lainscak M, Podbregar M. Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. Clin Res Cardiol: official journal of the German Cardiac Society. 2008;97(1):24-31.
Watanabe K, Ohta Y, Inoue M, Ma M, Wahed MII, Nakazawa M, et al. Bisoprolol Improves Survival in Rats with Heart Failure. J. Cardiovasc. 2001;38: S55-S8.
Villecco AS, Cocci C, Di Emidio M. Blood pressure control and weight loss in overweight or obese patients with previously treated or untreated mild to moderate hypertension given valsartan: An open-label study comparing pretreatment and posttreatment values. Curr Ther Res Clin Exp. 2004;65(2):172-84.
Fogari R, Derosa G, Zoppi A, Rinaldi A, Lazzari P, Fogari E, et al. Comparison of the Effects of Valsartan and Felodipine on Plasma Leptin and Insulin Sensitivity in Hypertensive Obese Patients. Hypertens. Res. 2005;28(3):209-14.
Sugimoto K, Qi NR, Kazdová L, Pravenec M, Ogihara T, Kurtz TW. Telmisartan but not valsartan increases caloric ex-penditure and protects against weight gain and hepatic steatosis. J. Hypertens. 2006;47(5):1003-9.
Ajwa N, Makhdoum L, Alkhateeb H, Alsaadoun A, Alqutub S, Alkhumayes H. The impact of orthodontic appliance on body weight changes, dietary habits, and self-perceived discomfort in early stages of orthodontic treatment. Glob J Health Sci. 2018; 10:11-7.
Gnanasambandam V, Gnaneswar SM. Effects of orthodontic treatment on body mass index, food habits and self-esteem of patients: A prospective single-arm cohort study. Taibah Univ. Medical Sci. 2022;17(5):818-25.
Sandeep KS, Singaraju GS, Reddy VK, Mandava P, Bhavikati VN, Reddy R. Evaluation of body weight, body mass index, and body fat percentage changes in early stages of fixed orthodontic therapy. J Int Soc Prev Community Dent. 2016;6(4):349-58.
Negrutiu BM, Todor BI, Moca A, Vaida LL, Pusta CJ. Dietary habits and weight loss in orthodontic patients. Hum. Vet. Med. Copy. 2019;11(2):57-60.
Shalchi M, Roshan MM, Imani MM, Aghajani R, Khabbaz S, Haghshenas ES. Evaluation of Pain, Dietary Intake, Body Mass Index, and Periodontal Status in Patients Undergoing Fixed Orthodontic Treatment with Bite Raiser. Cureus. 2022;14(12).
AAbudulameer AG, Saloom HF. The Effect of Nano Calcium Carbonate and/or Recombinant Bone Morphogenetic Protein as a Biological Orthodontic Retainer on the Body Weight of Experimental Rat. Cureus. 2023;15(1).
Hussein ZK, Saloom HF. Impact of Fixed Orthodontic Appliance with Diabetes Mellitus and Curcumin on the Body Weight of Experimental Rat. Journal of Research in Medical and Dental Science. 2020; 8:42-8.